Pearl Health raised $110 million on July 8, 2026, to expand the technology and financial infrastructure it provides to primary-care practices treating Medicare patients. The headline number combines two different forms of capital: a $50 million equity investment led by Andreessen Horowitz (better known as a16z) and a $60 million credit facility led by Trinity Capital.[1][2]
That distinction matters. Pearl did not sell $110 million of new stock. It sold equity for $50 million and secured the ability to borrow up to $60 million under a debt agreement. The equity can fund long-term expansion without a scheduled repayment. The debt can extend Pearl's runway with less ownership dilution, but borrowed amounts must be repaid with interest.
The round is a large bet on a specific future for independent medicine.
Pearl is trying to give small and midsize primary-care groups the data, contracts, workflows, and risk management they need to participate in Medicare value-based care without selling themselves to a hospital or insurer. It is not a concierge company. It works inside insurance-based Medicare. But its underlying argument will sound familiar to anyone tracking physician independence: a doctor-owned practice can survive if its economics and operating tools improve.
The Financing at a Glance
Component | Amount | Lead | Other participants | What it does |
|---|---|---|---|---|
Equity investment | $50 million | Andreessen Horowitz | Viking Global Investors, AlleyCorp, Ulysses Capital | Adds permanent capital in exchange for ownership |
Credit facility | $60 million | Trinity Capital | Not disclosed | Creates borrowing capacity that can be drawn under agreed conditions and repaid with interest |
Total announced capital | $110 million | Two separate leads | Five named capital providers | Combines ownership capital with repayable debt capacity |
Pearl says it will use the capital to expand its artificial intelligence (AI) platform, develop new risk offerings, move further into Medicare Advantage, and grow partnerships with health systems and insurers.[1][2] MobiHealthNews reported that the New York company reached profitability in 2025.[1] Pearl's corrected press release added a projection of $500 million in gross healthcare-system savings and a patient base three times its 2024 size by the end of 2026.[3] Those forward-looking figures come from the company and should be treated as targets, not audited outcomes.
What Pearl Health Actually Does
Pearl gives primary-care physicians a way to participate in value-based Medicare contracts. In fee-for-service medicine, a practice is generally paid for visits and procedures. In value-based care, payment is tied partly to quality, outcomes, and the total cost of caring for a defined patient population.
That creates a difficult operating problem for an independent practice. A physician needs to know which patients were recently hospitalized, who has an overdue annual wellness visit, where medication or follow-up gaps exist, and which patients with multiple chronic conditions need attention first. The practice must also understand contract rules, document patient complexity, report performance, and manage the possibility of shared financial losses.
Pearl's platform pulls those tasks into one operating layer. It uses claims and clinical data to prioritize patients, surfaces hospital admissions and discharges, tracks quality measures, and recommends care-team actions.[1][4] Pearl also supplies contracting, reporting, and financial-risk infrastructure. The product is closer to an operating system for Medicare risk than a conventional electronic health record.
The company reported in March 2026 that it had managed care for nearly 600,000 Medicare beneficiaries over five years, facilitated more than 370,000 care events, overseen more than $5 billion in healthcare costs, and worked across 43 states with more than 8,000 providers.[5] By July, the financing announcement described a network of more than 10,000 providers in over 40 states.[3] These are Pearl's own scale figures, but the direction is clear: the company has moved well beyond a small software pilot.
Pearl has also announced partnerships with Accountable Health Partners, a network affiliated with the University of Rochester Medical Center; MDX Hawai'i, which includes more than 630 primary-care physicians and 2,300 specialists and other providers; Walgreens; Virginia Care Partners; Wellcare; Synapticure; and DeepScribe.[1] That mix shows the next stage of the business. Pearl began by enabling independent physicians, but it now wants larger health systems, physician networks, and health plans as enterprise customers.
Founders and Origin
Pearl Health was founded in New York in 2020 by Michael Kopko, Ankit Patel, Dr. Jeffrey De Flavio, and Kevin Ryan.[6][7]
Kopko, Pearl's chief executive, was an early employee and vice president at Oscar Health, where he built sales and provider-network functions and later managed a business line with more than $2.5 billion in profit-and-loss responsibility. Before Oscar, he worked in research and analytics at Bridgewater Associates.[7]
Dr. De Flavio brought the clinical and value-based-care background. He founded Groups Recover Together, an opioid-use-disorder treatment company built around value-based contracts, and became an entrepreneur in residence at AlleyCorp.[7] Ryan is the New York technology founder behind AlleyCorp and a co-founder of companies including MongoDB, Business Insider, Gilt Groupe, Zola, and Nomad Health.[7][8] AlleyCorp lists Pearl as an incubation and names all four founders.[6]
The combination explains Pearl's design. Kopko understood insurance networks and healthcare spending. De Flavio understood clinical redesign and risk contracts. Ryan and AlleyCorp supplied the company-building environment. The original product idea was never simply another dashboard. It was a way to make individual physicians capable of carrying financial risk that previously required a large health system, insurer, or national medical group.
a16z Keeps Leading Pearl's Rounds
In September 2021, a16z led Pearl's $18 million Series A, with AlleyCorp and Kevin Ryan following.[9] Vineeta Agarwala, a physician and general partner on a16z's Bio + Health team, joined Pearl's board. In January 2023, a16z's Growth Fund and Viking Global Investors led a $55 million equity investment, paired with an anticipated $20 million credit line.[4] Now a16z is leading the new $50 million equity round, while Agarwala remains listed as a Pearl director.[7]
This is three consecutive institutional rounds with a16z in the lead. That is more informative than a famous name appearing once in a press release. It means the firm has repeatedly reviewed Pearl's operating data, market position, and execution from a board-level vantage point and decided to invest again.
a16z's thesis has also stayed unusually consistent. In its 2021 investment memo, Agarwala described primary-care physicians as the central decision-makers in healthcare spending and argued that technology could let independent doctors participate directly in value-based contracts.[10] The firm saw Pearl as a three-part business: physician exposure to financial risk, software for new clinical workflows, and a marketplace connecting doctors, payers, and specialized care partners.[10]
The 2026 investment suggests a16z believes that thesis is beginning to work at scale. Agarwala's financing statement emphasized that Pearl can manage risk through technology instead of expanding a large employed clinical workforce.[1] That point matters for the business model. A software and risk-infrastructure company can add physician groups without hiring a proportional number of doctors, nurses, and care managers. If the model works, revenue and managed lives can grow faster than payroll.
There is still a concentration risk in that story. A board investor leading round after round can signal conviction, but it also means much of the external validation comes from an existing insider. Pearl did not disclose a new equity lead, its valuation, the ownership sold, or whether the latest round changed board control.
The Other Equity Investors
The rest of the syndicate fills different roles.
Viking Global Investors is the other major repeat growth investor. Viking co-led Pearl's 2023 equity round and returned in 2026.[4] The firm invests in public and private companies and maintains a substantial healthcare and life-sciences portfolio.[11] Its return matters because Viking evaluates private companies with the financial discipline of an investor that also operates in public markets. Pearl's reported 2025 profitability likely makes the company more legible to that kind of capital than an earlier-stage healthcare startup dependent entirely on future growth.
AlleyCorp is Pearl's company-building investor and the connection to co-founder Kevin Ryan. It participated in the Series A, the 2023 round, and the new financing.[4][6][9] AlleyCorp's presence is less about discovering Pearl late and more about maintaining ownership in a company it helped incubate. It also provides continuity between the founding team and the institutional investors.
Ulysses Capital is named as a participant in the new equity round, but Pearl did not disclose the size of its check, whether it had invested before, or the investment vehicle involved.[1][2] That limited disclosure is worth preserving. Private financing announcements often name a syndicate without revealing who bought how much or on what terms.
Together, the equity group is mostly returning capital. That can reduce financing risk because the investors already know the company. It can also mean the round provides less independent price discovery than a financing led by a new outside firm. Pearl did not announce a valuation, so the market cannot tell how much the company was worth before or after the round.
How the $60 Million Debt Deal Works
The cleanest way to read the debt is as capacity, not cash that necessarily arrived in Pearl's bank account on July 8.
A credit facility is an agreement under which a lender commits to make financing available, usually subject to conditions in the loan documents. Pearl can draw eligible amounts when it needs them, up to the facility limit. Interest is generally charged on the amount borrowed, and facilities may also include fees on committed but unused capacity. Drawn principal must be repaid on a schedule or at maturity.
Trinity Capital describes its technology-lending product as senior or subordinated venture debt that can be paired with an equity financing and used for growth or working capital while limiting shareholder dilution.[12] For Pearl, that means the $60 million can fund product development, enterprise implementations, working capital, or the cash demands created by new risk arrangements without selling another $60 million of stock.
The tradeoff is straightforward:
Equity | Debt facility |
|---|---|
Does not have a scheduled principal repayment | Borrowed principal must be repaid |
Dilutes founders and existing shareholders | Usually creates less dilution |
Investor return depends mainly on company value | Lender receives interest, fees, and sometimes warrants |
Absorbs operating losses more flexibly | Can include covenants, collateral, draw conditions, and default remedies |
Expensive if the company becomes much more valuable | Expensive if cash flow cannot comfortably service it |
Pearl and Trinity have not publicly disclosed the facility's interest rate, maturity, collateral package, repayment schedule, covenants, draw conditions, or whether Trinity received warrants. It would be inaccurate to fill those gaps with standard venture-debt terms. We can explain the structure, but not Pearl's private pricing.
What is public is the pattern. Pearl's 2023 financing also combined equity and debt: $55 million of equity plus an anticipated $20 million line of credit.[4] The 2026 package uses the same architecture, with slightly less new equity and three times the announced debt capacity. That change likely reflects greater confidence in Pearl's cash flow after profitability, larger working-capital needs, or both. It is an inference, because Pearl has not explained why it chose the precise 50-to-60 split.
Debt can be especially useful in a risk-bearing healthcare business. Revenue, shared-savings payments, and settlement obligations may arrive on different schedules. New contracts can require investment in data integration and practice support before their full economics are visible. A facility lets Pearl match borrowing more closely to those needs instead of raising equity for every temporary cash demand.
It also adds risk. Value-based-care results can vary by patient population, contract design, benchmark changes, and medical-cost trends. CMS changed ACO REACH's 2026 financial methodology, including risk-score constraints, benchmark weighting, risk corridors, and the quality withhold.[13] If cash generation weakens while Pearl has debt outstanding, interest and repayment obligations do not disappear. Profitability makes debt more sensible, but it does not make debt free.
Why Medicare Policy Is the Real Market Behind Pearl
Pearl's market exists because Medicare is shifting more primary care into accountable care organizations and risk-based payment models.
Under the Centers for Medicare & Medicaid Services' ACO REACH model, participating organizations coordinate care for people in Original Medicare and can share in savings or losses. The professional track exposes an organization to 50% of savings and losses. The global track exposes it to 100%, with risk-adjusted monthly payment options.[13] That is a meaningful financial responsibility for a small practice.
Pearl sits between the physician and that complexity. It aggregates practices, supplies technology, translates claims into workflows, and helps manage contract economics. The physician can remain locally owned while gaining some of the infrastructure of a national organization.
This is why Pearl belongs on the Practice-Tech watchlist. AI tools are already taking over administrative work inside independent practices. Pearl operates one layer higher. It is automating the financial and population-health work required to manage an entire Medicare panel.
What This Means for Independent, Concierge, and DPC Practices
Pearl's direct customer is an insurance-based provider or organization, not a patient shopping for membership medicine. A concierge practice charges a membership fee for more time and access. Direct primary care removes most insurance billing from the primary-care relationship. Pearl takes the opposite route: it keeps the practice inside Medicare and makes the insurance and risk layer more manageable.
The models still respond to the same pressure. Traditional primary care produces too much administrative work and too little control for many physicians. Some doctors leave for membership medicine. Others want to keep serving broad Medicare populations but need better economics and infrastructure. Pearl is building for the second group.
That makes the financing a supply-side signal for NextMD. Better risk and workflow tools could help more physician-owned primary-care practices remain independent. It may also slow the path by which burned-out doctors sell to hospital systems or leave insurance entirely. For patients, the hoped-for result is more proactive outreach after a hospitalization, better chronic-care follow-up, and a practice that can stay open without becoming part of a national chain.
The limits are important. Pearl does not guarantee a smaller patient panel, same-day access, longer visits, or a direct relationship with one doctor. Those are features patients should evaluate separately when comparing a Medicare practice with concierge and DPC options. Its AI recommendations also remain tools for care teams, not substitutes for clinical judgment.
For Pearl's hometown market, the stakes are easy to see. New York contains large health systems and hundreds of independent practices competing for the same physicians and Medicare patients. Technology that makes independent risk contracts workable can influence who remains independent and who consolidates.
The Bottom Line
Pearl Health's $110 million announcement is best understood as a $50 million equity vote of confidence plus a $60 million borrowing tool. a16z's third consecutive lead is the strongest investor signal. Viking and AlleyCorp add repeat growth and founder-aligned capital. Trinity Capital adds a large, less-dilutive pool that Pearl can use as it expands, with repayment risk that the headline does not show.
The capital is funding a clear thesis: independent primary-care doctors should be able to manage Medicare risk with software and shared infrastructure instead of giving up ownership. Pearl has reported the scale, partnerships, and profitability needed to make that thesis credible. The next proof points are harder. It must show that its AI produces durable clinical and financial results, that enterprise growth does not pull it away from small practices, and that the debt-funded expansion generates enough cash to justify the obligation.
Sources
Hagen, J. (2026). Pearl Health lands $110M to expand AI platform for Medicare providers. MobiHealthNews. Read on MobiHealthNews
Cooley LLP. (2026). Pearl Health Raises $110 Million. Read the transaction coverage
Pearl Health. (2026). Pearl Health Raises $110 Million to Expand Its AI Platform Helping Providers Deliver Better Outcomes at Lower Cost for Medicare Patients. PR Newswire. Read the corrected financing announcement
Pearl Health. (2023). Pearl Health raises $75M to fuel growth, diversify offerings, and accelerate value-based care innovation. Read the Series B announcement
Pearl Health. (2026). The 43-State View: What National Scale in Primary Care Enablement Actually Teaches You. Read Pearl's scale report
AlleyCorp. (2026). Pearl Health. View the company profile
Pearl Health. (2026). Our Team. View Pearl's leadership and board
AlleyCorp. (2026). Kevin Ryan. View the founder profile
Pearl Health. (2021). Pearl Health raises $18M led by a16z to create an efficient marketplace for healthcare risk. Read the Series A announcement
Agarwala, V. (2021). Investing in Pearl Health. Andreessen Horowitz. Read the original investment thesis
Viking Global Investors. (2026). Private Equity Portfolio. View Viking's portfolio
Trinity Capital. (2026). Tech Lending: Venture Debt Financing for Tech Companies. Read Trinity's lending overview
Centers for Medicare & Medicaid Services. (2026). ACO REACH Model. Read the model details